Dapagliflozin: drug profile and its role in individualized treatment.

about

Dapagliflozin: drug profile and its role in individualized treatment.

Item

http://www.wikidata.org/entity/Q38308333

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dapagliflozin: drug profile and its role in individualized treatment.

@en

type

Item

label

Dapagliflozin: drug profile and its role in individualized treatment.

@en

prefLabel

Dapagliflozin: drug profile and its role in individualized treatment.

@en

P1476

Dapagliflozin: drug profile and its role in individualized treatment

@en

P2093

Georgina Sposetti

http://www.w3.org/2001/XMLSchema#string

Ignacio MacKinnon

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular analysis of the SGLT2 gene in patients with renal glucosuria

Active sugar transport in health and disease

Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

P304

129-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14779072.2015.995636

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Noël C. Barengo

P577

2015-01-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25560982

http://www.w3.org/2001/XMLSchema#string

P921

dapagliflozin